Ex-adviser associate settles SEC insider trading case, pays $143,000

A former senior associate at a New York investment advisory firm has agreed to pay roughly $143,000 and step away from the advice and brokerage industry for two years to settle SEC allegations that he traded biotech stocks in a relative's account using confidential deal data. 

The SEC says Rakesh Ahuja, 42, spent years inside the wall-cross process at an SEC-registered advisory firm, sizing up biopharma and biotech companies for two pooled funds the firm managed. That access, according to the regulator, came with confidential clinical trial data, PIPE financing plans, and other material nonpublic information the firm had agreed to keep under wraps. 

Instead of keeping it under wraps, the SEC alleges, Ahuja used it. 

From at least June 2022 through July 2023, he is accused of directing trades in a brokerage account belonging to a close relative, buying shares of three Nasdaq-listed biotechs just before market-moving announcements on four occasions. The tickers: X4 Pharmaceuticals (XFOR), UroGen Pharma (URGN), and Black Diamond Therapeutics (BDTX). For X4 Pharma and UroGen, the SEC says one of the funds Ahuja was helping evaluate the deal for ended up participating in the private placement tied to the announcement. 

The payoff, according to the regulator, was about $65,404 in illicit profits. The biggest single move came from Black Diamond, whose stock rose 235.87 percent the day it released positive clinical data in June 2023. Ahuja allegedly bought 9,000 shares in the days before the announcement and sold them all the same day the news hit. 

The story gets worse from there. When FINRA circulated trader identification lists to the firm in late 2023 and early 2024, asking staff whether they recognized any of the names flagged for trading around the UroGen and Black Diamond announcements, Ahuja's close relative was listed on the first page of both. He twice told his employer he did not recognize anyone, the SEC alleges. Three days after the second response, he resigned. 

Without admitting or denying the allegations, Ahuja consented to the entry of a final judgment, subject to court approval. He agreed to a permanent injunction from violating Section 10(b) of the Securities Exchange Act and Rule 10b-5, a two-year bar from acting as or being associated with an investment adviser, broker, or dealer, and monetary sanctions totaling about $143,000: disgorgement of $65,404.25, prejudgment interest of $12,289.01, and a civil penalty of $65,404.25. The filing is Securities and Exchange Commission v. Rakesh Ahuja, No. 1:26-cv-03213 (S.D.N.Y.). 

For advisory firms, the settlement hits close to home. The firm had confidentiality agreements in place. It had a written policy barring personnel and their related parties from trading portfolio-company stock on nonpublic information. It had an attestation process tied to FINRA's surveillance inquiries. And still, the SEC alleges, a single employee with access to the wall-cross allegedly slipped through every layer. The SEC credited FINRA for its assistance in the investigation. 

That is the part likely to stick with compliance officers. The case is a reminder that related-party accounts, wall-cross attestations, and FINRA ID list responses are only as strong as the people filling them out, and that event-driven strategies in biotech sit squarely in the SEC's line of sight.